{"hands_on_practices": [{"introduction": "Understanding lymphocyte trafficking begins with its foundational mechanism: the leukocyte adhesion cascade. This multi-step process is orchestrated by a precise sequence of molecular interactions. This first exercise [@problem_id:2889122] challenges you to apply this framework in a thought experiment, predicting the consequences of a specific genetic knockout. By working through this problem, you will sharpen your ability to connect a molecular-level defect—in this case, impaired protein glycosylation—to its cascading effects on cell adhesion, tissue homing, and the ultimate inflammatory outcome.", "problem": "A research team uses Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) to generate a precise deletion of the gene encoding Core $2$ $\\beta$-$1,6$-$N$-acetylglucosaminyltransferase $1$ (C$2$GnT$1$, also known as GCNT$1$) specifically in murine T cells. The goal is to probe how loss of Core $2$ O-glycan branching on T-cell glycoproteins affects cutaneous homing during inflammation. In vitro, both wild-type and C$2$GnT$1$-deficient T cells are activated and polarized under conditions that induce a skin-homing phenotype (high P-selectin glycoprotein ligand-$1$ [PSGL-$1$], cutaneous lymphocyte antigen [CLA], C-C chemokine receptor $4$ [CCR$4$], and C-C chemokine receptor $10$ [CCR$10$]). Equal numbers of fluorescently distinguishable wild-type and C$2$GnT$1$-deficient T cells are adoptively transferred into recipients in which a localized cutaneous delayed-type hypersensitivity reaction has been elicited, resulting in endothelial upregulation of E-selectin (endothelial-leukocyte adhesion molecule-$1$), P-selectin, intercellular adhesion molecule-$1$ (ICAM-$1$), vascular cell adhesion molecule-$1$ (VCAM-$1$), and presentation of chemokines C-C motif ligand $17$ (CCL$17$) and C-C motif ligand $27$ (CCL$27$) on dermal postcapillary venules.\n\nAs the fundamental base for your reasoning, use the leukocyte adhesion cascade and core definitions of selectin/chemokine/integrin-dependent steps: (i) initial tethering and rolling mediated by selectins recognizing sialylated, fucosylated O-glycans (often on a Core $2$ scaffold) on leukocyte ligands such as PSGL-$1$; (ii) chemokine-triggered inside-out activation of integrins such as lymphocyte function-associated antigen-$1$ (LFA-$1$) and very late antigen-$4$ (VLA-$4$); and (iii) firm arrest and diapedesis via integrin binding to ICAM-$1$ and VCAM-$1$. Assume no off-target edits and comparable activation status, viability, and T-cell receptor signaling between the two T-cell populations.\n\nWhich integrated pattern of phenotypic markers and in vivo trafficking outcomes is most consistent with C$2$GnT$1$ loss in T cells in this skin-inflammation model?\n\nA. Markedly reduced binding of E-selectin–Fc and P-selectin–Fc chimeras and reduced HECA-$452$ (CLA) staining on C$2$GnT$1$-deficient T cells; decreased intravital microscopy rolling flux and fewer firm arrests in inflamed dermal venules; reduced accumulation in inflamed skin and attenuated ear swelling; preserved chemotaxis to CCL$27$ and normal ex vivo cytokine production.\n\nB. Enhanced firm adhesion in inflamed dermal venules because loss of bulky O-glycans facilitates integrin access to ICAM-$1$ and VCAM-$1$; increased accumulation in inflamed skin and exacerbated ear swelling; reduced need for selectin-mediated rolling.\n\nC. Impaired homing to peripheral lymph nodes due to defective L-selectin ligand biosynthesis, leading to reduced T-cell priming; cutaneous inflammation is diminished primarily because fewer effector T cells are generated.\n\nD. Normal trafficking into inflamed skin but reduced effector function because C$2$GnT$1$ loss diminishes CCR$4$ surface expression; chemotaxis to CCL$17$ and CCL$27$ is impaired while selectin-dependent interactions are intact.\n\nE. Preserved rolling due to compensation by Core $1$ O-glycans on PSGL-$1$, but defective egress from skin because C$2$GnT$1$ loss reduces sphingosine-$1$-phosphate receptor-$1$ (S$1$PR$1$); accumulation in skin is increased due to retention.", "solution": "The problem statement must first be validated for scientific soundness, consistency, and a well-posed structure.\n\n**Step 1: Extract Givens**\n- **Genetic Model:** T-cell specific deletion of Core $2$ $\\beta$-$1,6$-$N$-acetylglucosaminyltransferase $1$ (C$2$GnT$1$).\n- **Cell Populations:** Wild-type (WT) T cells and C$2$GnT$1$-deficient T cells.\n- **In Vitro Conditions:** Cells are activated and polarized to a skin-homing phenotype, expressing high levels of P-selectin glycoprotein ligand-$1$ (PSGL-$1$), cutaneous lymphocyte antigen (CLA), C-C chemokine receptor $4$ (CCR$4$), and C-C chemokine receptor $10$ (CCR$10$).\n- **In Vivo Model:** Adoptive transfer of equal numbers of fluorescently tagged WT and C$2$GnT$1$-deficient T cells into a recipient with a cutaneous delayed-type hypersensitivity (DTH) reaction.\n- **Inflammatory Environment:** Endothelial upregulation of E-selectin, P-selectin, intercellular adhesion molecule-$1$ (ICAM-$1$), vascular cell adhesion molecule-$1$ (VCAM-$1$). Presentation of chemokines C-C motif ligand $17$ (CCL$17$) and C-C motif ligand $27$ (CCL$27$).\n- **Fundamental Principles:** The solution must be based on the leukocyte adhesion cascade: (i) Selectin-mediated tethering/rolling via recognition of sialylated, fucosylated O-glycans, often on a Core $2$ scaffold. (ii) Chemokine-triggered integrin activation. (iii) Integrin-mediated firm arrest via binding to ICAM-$1$/VCAM-$1$.\n- **Assumptions:** No off-target CRISPR edits; comparable activation status, viability, and T-cell receptor signaling between WT and mutant cells.\n\n**Step 2: Validate Using Extracted Givens**\nThe problem statement is scientifically valid.\n- **Scientifically Grounded:** The role of C$2$GnT$1$ in synthesizing Core $2$ O-glycans, and the critical importance of these glycans for the function of selectin ligands (PSGL-$1$ for P-selectin, and CLA/PSGL-$1$ for E-selectin) are cornerstones of glycobiology and immunology. The leukocyte adhesion cascade is a fundamental, universally accepted model of leukocyte trafficking. The experimental setup (conditional knockout, adoptive transfer, DTH model) is standard and appropriate for the question asked.\n- **Well-Posed:** The problem provides sufficient information to deduce a unique outcome based on established biological principles. The question is precise and asks for the most consistent set of outcomes.\n- **Objective:** The language is technical and devoid of subjective or ambiguous terminology.\n\n**Verdict:** The problem is valid. The solution process may proceed.\n\n**Principle-Based Derivation**\nThe enzyme C$2$GnT$1$ is essential for initiating the formation of Core $2$ O-glycans by adding an $N$-acetylglucosamine (GlcNAc) residue in a $\\beta$-$1,6$ linkage to a Core $1$ O-glycan precursor ($Gal\\beta1$-$3GalNAc\\alpha1$-Ser/Thr). The resulting branched Core $2$ structure is the preferred scaffold for the subsequent addition of sialic acid and fucose to generate high-avidity ligands for E-selectin and P-selectin.\n\nThe primary E-selectin ligand on skin-homing T cells is the cutaneous lymphocyte antigen (CLA), an epitope defined by the HECA-$452$ antibody, which consists of sialyl Lewis X (sLe$^{x}$) presented on various protein backbones, most prominently PSGL-$1$. The primary P-selectin ligand is PSGL-$1$. The synthesis of functional, high-avidity versions of both these ligands is critically dependent on Core $2$ O-glycosylation.\n\nTherefore, deleting $C2GnT1$ in T cells will prevent the formation of Core $2$ O-glycans. This will lead to:\n$1$. **Defective Selectin Ligand Synthesis:** The T cells will be unable to synthesize functional CLA and high-affinity P-selectin ligands on PSGL-$1$. This defect is directly measurable as reduced binding of soluble E-selectin and P-selectin chimeras (e.g., E-selectin–Fc) and reduced staining with the CLA-specific antibody, HECA-$452$.\n$2$. **Impaired Adhesion Cascade Step (i):** The leukocyte adhesion cascade begins with tethering and rolling, a step mediated by selectins on endothelium binding to their ligands on leukocytes. Since the $C2GnT1$-deficient T cells lack functional E- and P-selectin ligands, they will fail to efficiently tether to and roll on the inflamed dermal venules, where E-selectin and P-selectin are upregulated. This would manifest as a greatly reduced rolling flux in intravital microscopy studies.\n$3$. **Impaired Adhesion Cascade Step (iii):** Rolling and tethering are prerequisites for firm arrest. The rolling motion slows the leukocyte sufficiently to allow it to sense and respond to endothelium-bound chemokines (CCL$17$, CCL$27$), which trigger the activation of integrins (LFA-$1$, VLA-$4$). Without efficient rolling, the cells will move too quickly past the inflamed site to receive the necessary chemokine signals for firm arrest. Consequently, the number of firmly arrested $C2GnT1$-deficient T cells will be drastically reduced.\n$4$. **Reduced Tissue Infiltration and Inflammation:** The failure to execute the adhesion cascade results in a failure to extravasate from the blood into the inflamed skin tissue. This will lead to a reduced accumulation of $C2GnT1$-deficient T cells at the site of the DTH reaction. As effector T cells are key mediators of DTH, their reduced presence will cause an attenuation of the inflammatory response, measurable as reduced ear swelling.\n$5$. **Preserved Chemokine and Effector Functions:** The problem states to assume comparable activation status and does not provide any basis to assume that C$2$GnT$1$, a glycosyltransferase, directly regulates chemokine receptor expression/signaling or cytokine production pathways. Therefore, it is logical to conclude that intrinsic chemotaxis towards CCL$17$/CCL$27$ and the capacity to produce cytokines upon stimulation remain intact.\n\n**Option-by-Option Analysis**\n\n**A. Markedly reduced binding of E-selectin–Fc and P-selectin–Fc chimeras and reduced HECA-$452$ (CLA) staining on C$2$GnT$1$-deficient T cells; decreased intravital microscopy rolling flux and fewer firm arrests in inflamed dermal venules; reduced accumulation in inflamed skin and attenuated ear swelling; preserved chemotaxis to CCL$27$ and normal ex vivo cytokine production.**\n- **Evaluation:** This option is fully consistent with the derived consequences. It correctly identifies the molecular defect (loss of selectin ligands), the resulting trafficking defect (impaired rolling and arrest), the macroscopic outcome (reduced accumulation and inflammation), and the preserved functions (chemotaxis, cytokine production).\n- **Verdict:** **Correct**.\n\n**B. Enhanced firm adhesion in inflamed dermal venules because loss of bulky O-glycans facilitates integrin access to ICAM-$1$ and VCAM-$1$; increased accumulation in inflamed skin and exacerbated ear swelling; reduced need for selectin-mediated rolling.**\n- **Evaluation:** This argument is fundamentally flawed. It ignores the sequential nature of the adhesion cascade, which is a required principle for this problem. Selectin-mediated rolling is not an optional step that can be bypassed; it is essential for bringing leukocytes into close enough contact with the endothelium at a slow enough speed to allow for chemokine signaling and subsequent integrin-mediated arrest. The hypothesis that removing O-glycans \"unmasks\" integrins is speculative and contradicts the established primary role of C$2$GnT$1$. The predicted outcomes are the opposite of what would occur.\n- **Verdict:** **Incorrect**.\n\n**C. Impaired homing to peripheral lymph nodes due to defective L-selectin ligand biosynthesis, leading to reduced T-cell priming; cutaneous inflammation is diminished primarily because fewer effector T cells are generated.**\n- **Evaluation:** This option mislocates the primary defect. The experiment tests the trafficking of *already generated* effector T cells into the *skin*, a process dependent on E- and P-selectin. Homing to lymph nodes via L-selectin and the process of T-cell priming are prior events not being tested in this experimental setup. The premise \"fewer effector T cells are generated\" contradicts the experimental design where equal numbers are transferred.\n- **Verdict:** **Incorrect**.\n\n**D. Normal trafficking into inflamed skin but reduced effector function because C$2$GnT$1$ loss diminishes CCR$4$ surface expression; chemotaxis to CCL$17$ and CCL$27$ is impaired while selectin-dependent interactions are intact.**\n- **Evaluation:** This option contains multiple falsehoods. The statement that \"selectin-dependent interactions are intact\" is the exact opposite of the primary consequence of C$2$GnT$1$ loss. Consequently, trafficking will not be normal. Furthermore, there is no established evidence that C$2$GnT$1$ loss primarily affects CCR$4$ expression to a degree that it becomes the principal defect. The central role of C$2$GnT$1$ is in selectin ligand biosynthesis.\n- **Verdict:** **Incorrect**.\n\n**E. Preserved rolling due to compensation by Core $1$ O-glycans on PSGL-$1$, but defective egress from skin because C$2$GnT$1$ loss reduces sphingosine-$1$-phosphate receptor-$1$ (S$1$PR$1$); accumulation in skin is increased due to retention.**\n- **Evaluation:** The premise of \"preserved rolling\" is incorrect. Core $1$ O-glycans are known to be poor substrates for forming high-avidity selectin ligands, and compensation is minimal. The primary defect is in tissue *entry*, not *egress*. The proposed link to S$1$PR$1$, the receptor for egress, is speculative and secondary to the profound and well-documented defect in entry. The predicted outcome of increased accumulation due to retention is therefore based on a faulty chain of reasoning and contradicts the expected reduction in cell entry.\n- **Verdict:** **Incorrect**.", "answer": "$$\\boxed{A}$$", "id": "2889122"}, {"introduction": "While the adhesion cascade provides a qualitative sequence of events, a quantitative understanding requires us to model the chemical cues that guide lymphocytes. Chemokine gradients are central to this process, but how are they formed and maintained within the complex tissue environment? This practice [@problem_id:2889119] introduces a reaction-diffusion model to describe a steady-state chemokine field. By solving for the chemokine concentration profile, you can directly link the rate of cell recruitment to the gradient's steepness, providing a powerful example of how biophysical principles can predict the efficacy of an anti-inflammatory drug.", "problem": "In inflamed human skin, T helper 17 (Th17) cells expressing CC chemokine receptor 6 (CCR6) enter the dermis by following gradients of Chemokine (C-C motif) ligand 20 (CCL20) emanating from the epidermis. Consider a one-dimensional dermal half-space $x \\geq 0$ with the epidermal surface at $x = 0$. Assume a steady-state CCL20 field $C(x)$ established by constant epidermal secretion and linear bulk removal in tissue, governed by the diffusion-degradation equation with constant coefficients,\n$$\nD\\,\\frac{d^{2}C}{dx^{2}} - k\\,C = 0,\n$$\nwhere $D$ is the effective diffusivity and $k$ is the first-order consumption rate constant. Take the boundary condition $C(0) = C_{0}$ (a fixed effective concentration proportional to the epidermal production rate) and $C(x) \\to 0$ as $x \\to \\infty$. A postcapillary venule at depth $x=L$ admits Th17 cells at a steady rate $R$ that is proportional to the local chemokine gradient steepness, consistent with linear chemotactic sensitivity in the low-occupancy regime, that is, $R \\propto \\left|\\frac{dC}{dx}\\big|_{x=L}\\right|$. Suppose an anti-inflammatory intervention reduces effective epidermal CCL20 production by $50\\%$ without altering $D$, $k$, $L$, or the proportionality between $C_{0}$ and the production rate. Under these assumptions, calculate the predicted fold-change in the steady-state Th17 cell entry rate into the venule relative to baseline. Express your answer as a unitless decimal. No rounding is required.", "solution": "The problem statement is scientifically grounded and mathematically well-posed. It presents a standard one-dimensional reaction-diffusion model at steady state, which is a valid and appropriate framework for analyzing the distribution of a signaling molecule in biological tissue. We will proceed with a formal solution.\n\nThe governing ordinary differential equation for the chemokine concentration, $C(x)$, is given as:\n$$\nD\\,\\frac{d^{2}C}{dx^{2}} - k\\,C = 0\n$$\nwhere $D$ and $k$ are positive constants representing diffusivity and consumption rate, respectively. This is a second-order linear homogeneous differential equation. We can write it as $\\frac{d^{2}C}{dx^{2}} - \\frac{k}{D}C = 0$. The characteristic equation is $r^2 - \\frac{k}{D} = 0$, which has the roots $r = \\pm\\sqrt{\\frac{k}{D}}$. The general solution for $C(x)$ is therefore:\n$$\nC(x) = A \\exp\\left(\\sqrt{\\frac{k}{D}} x\\right) + B \\exp\\left(-\\sqrt{\\frac{k}{D}} x\\right)\n$$\nwhere $A$ and $B$ are constants of integration to be determined by the boundary conditions.\n\nThe first boundary condition is that the concentration vanishes far from the source: $C(x) \\to 0$ as $x \\to \\infty$. In the general solution, the term $A \\exp\\left(\\sqrt{\\frac{k}{D}} x\\right)$ diverges as $x \\to \\infty$ because $\\sqrt{\\frac{k}{D}} > 0$. For the boundary condition to be satisfied, the coefficient $A$ must be zero. This simplifies the solution to:\n$$\nC(x) = B \\exp\\left(-\\sqrt{\\frac{k}{D}} x\\right)\n$$\nThe second boundary condition specifies the concentration at the epidermal surface: $C(0) = C_0$. Applying this to the simplified solution, we find:\n$$\nC(0) = B \\exp(0) = B\n$$\nThus, $B = C_0$. The specific solution for the concentration profile is:\n$$\nC(x) = C_0 \\exp\\left(-\\sqrt{\\frac{k}{D}} x\\right)\n$$\nThe problem states that the rate of Th17 cell entry, $R$, into a venule at depth $x=L$ is proportional to the magnitude of the local chemokine gradient. Let $\\gamma$ be the positive constant of proportionality. The rate is given by:\n$$\nR = \\gamma \\left|\\frac{dC}{dx}\\right|_{x=L}\n$$\nFirst, we compute the gradient of the concentration field, $\\frac{dC}{dx}$:\n$$\n\\frac{dC}{dx} = \\frac{d}{dx}\\left[C_0 \\exp\\left(-\\sqrt{\\frac{k}{D}} x\\right)\\right] = -C_0 \\sqrt{\\frac{k}{D}} \\exp\\left(-\\sqrt{\\frac{k}{D}} x\\right)\n$$\nNext, we evaluate this gradient at the position of the venule, $x=L$:\n$$\n\\frac{dC}{dx}\\bigg|_{x=L} = -C_0 \\sqrt{\\frac{k}{D}} \\exp\\left(-\\sqrt{\\frac{k}{D}} L\\right)\n$$\nThe magnitude of this gradient is positive, as $C_0$, $k$, and $D$ are positive constants. The rate of cell entry is then:\n$$\nR = \\gamma \\left|-C_0 \\sqrt{\\frac{k}{D}} \\exp\\left(-\\sqrt{\\frac{k}{D}} L\\right)\\right| = \\gamma C_0 \\sqrt{\\frac{k}{D}} \\exp\\left(-\\sqrt{\\frac{k}{D}} L\\right)\n$$\nThis expression demonstrates that the cell entry rate $R$ is directly proportional to the boundary concentration $C_0$, as all other parameters ($\\gamma$, $k$, $D$, $L$) are held constant.\n\nLet us denote the baseline (initial) state with subscript $b$ and the post-intervention state with subscript $a$ (for \"after\").\nThe baseline rate, $R_b$, is given by the expression derived above with the initial boundary concentration, $C_{0,b}$:\n$$\nR_b = \\gamma C_{0,b} \\sqrt{\\frac{k}{D}} \\exp\\left(-\\sqrt{\\frac{k}{D}} L\\right)\n$$\nThe intervention consists of reducing the epidermal CCL20 production by $50\\%$. The problem states that $C_0$ is proportional to this production rate. Therefore, the new boundary concentration, $C_{0,a}$, is $50\\%$ of the baseline concentration:\n$$\nC_{0,a} = 0.5 \\times C_{0,b}\n$$\nThe new cell entry rate, $R_a$, is found by substituting $C_{0,a}$ into the rate equation, as all other parameters are unchanged:\n$$\nR_a = \\gamma C_{0,a} \\sqrt{\\frac{k}{D}} \\exp\\left(-\\sqrt{\\frac{k}{D}} L\\right) = \\gamma (0.5 \\times C_{0,b}) \\sqrt{\\frac{k}{D}} \\exp\\left(-\\sqrt{\\frac{k}{D}} L\\right)\n$$\nBy inspection, we can relate the new rate $R_a$ to the baseline rate $R_b$:\n$$\nR_a = 0.5 \\times \\left(\\gamma C_{0,b} \\sqrt{\\frac{k}{D}} \\exp\\left(-\\sqrt{\\frac{k}{D}} L\\right)\\right) = 0.5 \\times R_b\n$$\nThe question asks for the fold-change in the rate, which is the ratio of the new rate to the baseline rate, $\\frac{R_a}{R_b}$:\n$$\n\\frac{R_a}{R_b} = \\frac{0.5 \\times R_b}{R_b} = 0.5\n$$\nThe linearity of the governing differential equation and the rate law with respect to concentration ensures that a $50\\%$ reduction in the source term $C_0$ results in a corresponding $50\\%$ reduction in the cell entry rate.", "answer": "$$\n\\boxed{0.5}\n$$", "id": "2889119"}, {"introduction": "Once a T cell successfully navigates the journey into the skin, the next critical question becomes: how long does it stay? This is particularly relevant for tissue-resident memory T cells (T$_{\\text{RM}}$), whose longevity in tissue is key to local protective immunity. This final practice [@problem_id:2889157] simulates a common experimental approach to measure this, using data from a photoconversion experiment. You will learn to parse raw cell counts, account for experimental artifacts like background fluorescence, and fit the data to a first-order decay model to calculate the population's residence half-life, $t_{1/2}$.", "problem": "A localized population of tissue-resident memory T cells (T$_{\\text{RM}}$) is photoconverted in a defined skin region of interest (ROI) at time $t=0$. After photoconversion, only the photoconverted T$_{\\text{RM}}$ pool is tracked over time. Assume a first-order loss process in which the true number of photoconverted T$_{\\text{RM}}$, denoted $N(t)$, obeys $dN/dt=-k\\,N$ with constant rate $k>0$. The fluorescence-based measurement yields an observed count $M(t)$ that is the sum of a constant background $B$ and a constant fraction $\\eta$ of the true count, i.e., $M(t)=\\eta\\,N(t)+B$, where $B$ and $\\eta$ do not change over the experiment. The residence half-life is defined as the time $t_{1/2}$ such that $N(t_{1/2})=N(0)/2$.\n\nIn one experiment, independent calibration in an adjacent unconverted skin site yields a constant background $B=200$ cells per ROI. Optical throughput is characterized and is constant at $\\eta=0.80$. In the photoconverted ROI, the measured photoconverted counts are $M(0)=5200$, $M(7)=2900$, and $M(21)=980$ cells at times $t=0$, $t=7$, and $t=21$ days, respectively.\n\nStarting only from the first-order loss law $dN/dt=-k\\,N$ and the measurement model $M(t)=\\eta\\,N(t)+B$, derive an estimator for $k$ that eliminates the unknown initial $N(0)$ and the detection efficiency $\\eta$ using any two time points $t_{1}\\neq t_{2}$, and then use the time points $t_{1}=7$ and $t_{2}=21$ days to compute the residence half-life $t_{1/2}$. Express the final half-life in days and round your answer to four significant figures.", "solution": "The problem requires validation before a solution is attempted.\n\nStep 1: Extract Givens\nThe verbatim givens are as follows:\n- The true number of photoconverted T$_{\\text{RM}}$ cells, $N(t)$, follows the first-order loss process: $dN/dt=-k\\,N$, with a constant rate $k>0$.\n- The observed count, $M(t)$, is related to the true count $N(t)$ by the measurement model: $M(t)=\\eta\\,N(t)+B$.\n- The background $B$ and detection efficiency $\\eta$ are constant.\n- The residence half-life $t_{1/2}$ is defined as the time at which $N(t_{1/2})=N(0)/2$.\n- From an independent calibration, the constant background is $B=200$ cells per ROI.\n- The optical throughput is constant at $\\eta=0.80$.\n- Measured counts in the photoconverted ROI are:\n  - $M(0)=5200$ cells at $t=0$ days.\n  - $M(7)=2900$ cells at $t=7$ days.\n  - $M(21)=980$ cells at $t=21$ days.\n- The task is to derive an estimator for $k$ using two generic time points $t_1$ and $t_2$ ($t_1 \\ne t_2$) that eliminates $N(0)$ and $\\eta$.\n- Then, use the data at $t_1=7$ and $t_2=21$ days to compute the residence half-life $t_{1/2}$.\n- The final answer for the half-life must be in days and rounded to four significant figures.\n\nStep 2: Validate Using Extracted Givens\nThe problem is subjected to validation against the specified criteria.\n- **Scientifically Grounded**: The problem describes a first-order exponential decay process, a fundamental and widely applicable model in physics, chemistry, and biology for phenomena such as radioactive decay, chemical reaction kinetics, and population dynamics. The measurement model is a standard linear transformation, accounting for background noise and detection efficiency. This is a scientifically realistic and sound model for the described biological experiment.\n- **Well-Posed**: The problem is well-posed. It provides a differential equation with an initial condition (implied at $t=0$), a measurement model, and sufficient data points to determine the unknown parameters. The objective is clearly stated: derive a specific formula and then calculate a physical quantity.\n- **Objective**: The problem is stated in objective, quantitative language. All terms are defined mathematically. There are no subjective or ambiguous statements.\n- **Completeness**: The problem is self-contained. It provides all necessary equations, definitions, and data to arrive at a unique solution. The presence of extra information ($\\eta$ and $M(0)$) does not make the problem incomplete but rather serves as a test of whether the student correctly follows the instructions to derive an estimator independent of these parameters.\n- **Consistency**: The givens are consistent. The measured count $M(t)$ decreases over time, which is consistent with a decay process ($k>0$).\n\nStep 3: Verdict and Action\nThe problem is deemed **valid**. It is a standard problem in quantitative biology that tests the understanding of exponential decay models and data analysis. A complete solution will be provided.\n\nThe first-order linear ordinary differential equation governing the true number of cells $N(t)$ is\n$$\n\\frac{dN}{dt} = -k N\n$$\nThis equation is separable. Integrating from time $t=0$ to an arbitrary time $t$ yields:\n$$\n\\int_{N(0)}^{N(t)} \\frac{dN}{N} = \\int_{0}^{t} -k \\, d\\tau\n$$\n$$\n\\ln\\left(\\frac{N(t)}{N(0)}\\right) = -kt\n$$\nSolving for $N(t)$ gives the explicit solution for the true cell count:\n$$\nN(t) = N(0) \\exp(-kt)\n$$\nThe measurement model relates the observed count $M(t)$ to the true count $N(t)$:\n$$\nM(t) = \\eta N(t) + B\n$$\nSubstituting the expression for $N(t)$ into the measurement model, we obtain:\n$$\nM(t) = \\eta N(0) \\exp(-kt) + B\n$$\nTo derive an estimator for the rate constant $k$ that is independent of the initial true count $N(0)$ and the detection efficiency $\\eta$, we first isolate the exponential term. Let us define the background-subtracted measurement as $M'(t) = M(t) - B$.\n$$\nM'(t) = M(t) - B = \\eta N(0) \\exp(-kt)\n$$\nNow, we evaluate this expression at two distinct time points, $t_1$ and $t_2$:\n$$\nM'(t_1) = M(t_1) - B = \\eta N(0) \\exp(-kt_1) \\quad (1)\n$$\n$$\nM'(t_2) = M(t_2) - B = \\eta N(0) \\exp(-kt_2) \\quad (2)\n$$\nTo eliminate the product $\\eta N(0)$, we take the ratio of equation $(2)$ to equation $(1)$:\n$$\n\\frac{M'(t_2)}{M'(t_1)} = \\frac{M(t_2) - B}{M(t_1) - B} = \\frac{\\eta N(0) \\exp(-kt_2)}{\\eta N(0) \\exp(-kt_1)} = \\exp(-k(t_2 - t_1))\n$$\nTaking the natural logarithm of both sides isolates the exponent:\n$$\n\\ln\\left(\\frac{M(t_2) - B}{M(t_1) - B}\\right) = -k(t_2 - t_1)\n$$\nSolving for $k$ yields the desired estimator:\n$$\nk = -\\frac{1}{t_2 - t_1} \\ln\\left(\\frac{M(t_2) - B}{M(t_1) - B}\\right)\n$$\nThis can be rewritten using the properties of the logarithm, $\\ln(1/x) = -\\ln(x)$, as:\n$$\nk = \\frac{1}{t_2 - t_1} \\ln\\left(\\frac{M(t_1) - B}{M(t_2) - B}\\right)\n$$\nThis is the general estimator for $k$ that eliminates $N(0)$ and $\\eta$.\n\nNow, we use the provided data points $t_1=7$ days and $t_2=21$ days to compute a numerical value for $k$.\nThe givens are:\n$t_1 = 7$ days\n$t_2 = 21$ days\n$M(t_1) = M(7) = 2900$\n$M(t_2) = M(21) = 980$\n$B = 200$\n\nThe time interval is $t_2 - t_1 = 21 - 7 = 14$ days.\nThe background-subtracted counts are:\n$M(t_1) - B = 2900 - 200 = 2700$\n$M(t_2) - B = 980 - 200 = 780$\n\nSubstituting these values into the expression for $k$:\n$$\nk = \\frac{1}{14} \\ln\\left(\\frac{2700}{780}\\right) = \\frac{1}{14} \\ln\\left(\\frac{270}{78}\\right) = \\frac{1}{14} \\ln\\left(\\frac{45}{13}\\right)\n$$\nThe residence half-life $t_{1/2}$ is defined by the condition $N(t_{1/2}) = N(0)/2$. Using the solution $N(t) = N(0) \\exp(-kt)$:\n$$\nN(0) \\exp(-k t_{1/2}) = \\frac{N(0)}{2}\n$$\n$$\n\\exp(-k t_{1/2}) = \\frac{1}{2}\n$$\nTaking the natural logarithm of both sides:\n$$\n-k t_{1/2} = \\ln\\left(\\frac{1}{2}\\right) = -\\ln(2)\n$$\nThis gives the well-known formula for the half-life:\n$$\nt_{1/2} = \\frac{\\ln(2)}{k}\n$$\nSubstituting our expression for $k$:\n$$\nt_{1/2} = \\frac{\\ln(2)}{\\frac{1}{14} \\ln\\left(\\frac{45}{13}\\right)} = 14 \\frac{\\ln(2)}{\\ln\\left(\\frac{45}{13}\\right)}\n$$\nWe now compute the numerical value.\n$\\ln(2) \\approx 0.69314718$\n$\\ln(45/13) \\approx \\ln(3.46153846) \\approx 1.24170066$\n$$\nt_{1/2} = 14 \\times \\frac{0.69314718}{1.24170066} \\approx 14 \\times 0.5582316 \\approx 7.8152424\n$$\nThe problem requires the final answer to be rounded to four significant figures.\n$$\nt_{1/2} \\approx 7.815 \\text{ days}\n$$\nThe values for $\\eta=0.80$ and $M(0)=5200$ were not required for this calculation, as dictated by the problem's specific instructions to derive an estimator that eliminates these parameters. This confirms the correct application of the derived formula.", "answer": "$$\n\\boxed{7.815}\n$$", "id": "2889157"}]}